Globe Newswire (Tue, 7-Jul 8:30 AM ET)
Veru Establishes At-the-Market Equity Offering Program
TipRanks (Thu, 2-Jul 4:32 PM ET)
Globe Newswire (Wed, 13-May 6:30 AM ET)
Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th
Globe Newswire (Wed, 6-May 8:30 AM ET)
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Veru trades on the NASDAQ stock market under the symbol VERU.
As of July 7, 2026, VERU stock price climbed to $2.88 with 270,212 million shares trading.
VERU has a beta of 0.31, meaning it tends to be less sensitive to market movements. VERU has a correlation of 0.00 to the broad based SPY ETF.
VERU has a market cap of $46.23 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, VERU traded as high as $19.20 and as low as $2.05.
The top ETF exchange traded funds that VERU belongs to (by Net Assets): VTI, VXF, IWC.
VERU has underperformed the market in the last year with a price return of -52.5% while the SPY ETF gained +20.8%. However, in the short term, VERU had mixed performance relative to the market. It has outperformed in the last 3 months, returning +20.0% vs +13.8% return in SPY. But in the last 2 weeks, VERU shares have been beat by the market, returning -2.7% compared to an SPY return of +0.4%.
VERU support price is $2.66 and resistance is $3.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERU shares will trade within this expected range on the day.